SUMMARY
- OneCell Diagnostics raised $16M Series A, led by Celesta Capital, for OncoIndx Alfa launch.
- Utilizing single-cell multi-omics and liquid biopsy for personalized cancer diagnostics and care.
- Collaborates with Tata Memorial, AIIMS, Stanford, and Harvard; tested technology on 10,000 Indians.
OneCell Diagnostics, a cancer diagnostics startup, has raised $16 million in its Series A fundraising round led by Celesta Capital. According to the company, the fresh capital will be utilized to bring OncoIndx Alfa, a next-generation liquid biopsy test that finds circulating tumor cells, to the US market.
The round also included participation from Eragon, Singularity Ventures, Cedars Sinai, and Tenacity Ventures.
CEO and Co-founder of OneCell stated, “We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision. By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalized cancer care worldwide.
Michael Marks, Founding Managing Partner at Celesta Capital said, “Celesta is excited about differentiated companies sitting at the intersection of high tech and biomedical science, and OneCell fits this mold perfectly. By leveraging the strategic benefits of the U.S. – India corridor, OneCell is well-positioned to continue building competitive advantages. We pride ourselves on being active value-add investors and Celesta will tap our ecosystem to support their growth wherever possible.
Meanwhile, Dr. James Rothman, Nobel Laureate and Celesta Capital Advisor states, “I’m looking forward to joining the OneCell Board at such a pivotal time in the arc of innovation for cancer treatment. Cell biopsy represents a groundbreaking shift in how we approach diagnostics, creating more opportunities for highly individualized care. This technology has the potential to reshape the oncology landscape, and we are eager to support OneCell’s bold mission to reach more than 1000 oncologists and 1 million patients in the near future.
OneCell, which was founded in 2021, develops multi-omics biomarkers through the use of data analytics, AI/ML, powerful bioinformatics, and next-generation sequencing. OneCell has partnerships with Tata Memorial Centre and the All India Institute of Medical Science in New Delhi, according to its website. Stanford University and Harvard Medical School are only two of its strategic academic and business partners.
The company has tested its cell biopsy technology on about 10,000 people in India thus far, and has already launched a number of solutions.
